Disease-Focused Discovery
PureTech established the underlying programs and platforms that resulted in 24 products and product candidates that are being advanced within PureTech's Wholly Owned Pipeline or by its Founded Entities, including two products that have been cleared by the FDA and granted European marketing authorization.
View our corporate deck.
PureTech's Components of Value
Wholly Owned Pipeline
1 | Lymphatic flow disorders, incl. lymphedema | ~1M |
Product candidate for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., IPF, uILDs and Long COVID respiratory complications and related sequelae) and lymphedema.
1 | Long COVID respiratory complications & related sequelae |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
1 | Other fibrotic & inflammatory disorders, such as IPF | ~130K (IPF or uILD) |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-200 is a fully human IgG4 mAb that is designed to block galectin-9, which we are developing for the treatment of solid tumors, including PDAC, CRC and CCA, that do not respond to approved checkpoint inhibitors and have poor survival rates.
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-210 is a fully human IgG1 mAb directed against the δ1 chain of T cells bearing γδT cell receptors (TCRs) we are designing for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
Preclinical | Neurological indications |
LYT-300 is an oral form of FDA-approved allopregnanolone, which is currently marketed in the U.S. as ZulressoTM and administrated as a 60-hour intravenous infusion. An oral form of allopregnanolone and other neurosteroids would enable the development of these natural molecules for treating a range of neurological and neuropsychological conditions.
| Phase completed | Phase in progress |
Founded Entities
~$1B
Raised with Top-Tier Investors in Founded Entities since January 20172
Controlling Interest or Right to Receive Royalties
Developing novel therapies with the potential to transform the lives of people with disabling & potentially fatal neuropsychiatric disorders
Schizophrenia
~2.7M U.S.
Targeting the GI pathway to potentially alter the course of chronic diseases
EUROPEAN CE MARK GRANTED
Weight management
~150M U.S. (Overweight and obesity)
European CE Mark Granted
Adolescent weight management
~13.7M U.S.
Weight management in type 2 diabetes (T2D)/prediabetes
~30M U.S. (T2D)
~84M U.S. (Prediabetes)
Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease
~80-100M U.S.
Functional constipation
~35M U.S.
A regenerative platform designed to treat androgenetic alopecia, epithelial aging & other medical conditions
Androgenetic alopecia
~90M U.S.
High-risk Clostridioides difficile
~100-120K/year U.S.
Food allergy
~2.5M U.S. (Peanut allergy)
Solid tumors
>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)
Inflammatory bowel disease
~3M U.S.
Depression symptom change detection and monitoring
~17M U.S.
Oral delivery of biologics, vaccines & other drugs
Equity Interest Only
EUROPEAN CE MARK GRANTED
Pediatric ADHD
~6.4M U.S. (Pediatric ADHD)
European CE Mark Granted
Pediatric autism
Multiple sclerosis
Major depressive disorder
Major depressive disorder
Parkinson’s/MCI
Traumatic brain injury
ADHD caregiver app
Note: This figure represents the stage of development for each Founded Entity’s most advanced product candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of June 30, 2020, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., and Vor Biopharma Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of June 30, 2020, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor is based on the assumption that all future tranches of the most recent financing round are funded. Karuna ownership is calculated on an outstanding voting share basis as of October 31, 2020.
1. Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection.
2. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly. Funding figure assumes all future tranches are funded in the Vor Series B financing round. Calculated as of January 1, 2017 to June 30, 2020.
3. Important Safety Information: Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatine, or titanium dioxide. Plenity may alter the absorption of medications. Read Sections 6 and 8.3 of the Instructions for Use carefully. Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli, and rings; suspected strictures (such as patients with Crohn’s disease); or complications from prior gastrointestinal (GI) surgery that could affect GI transit and motility. Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or heartburn. The overall incidence of adverse events (AEs) in the Plenity group was no different than the placebo group. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. For the safe and proper use of Plenity, U.S. Instructions for Use or the EU Instructions for Use.
4. These product candidates are regulated as devices and their development has been approximately equated to phases of clinical development.
5. Products are investigational and have not been cleared by the FDA for use in the United States.
6. Contingent on FDA review of the research plan.
7. Future clinical research plans and priorities in process.
Cash at PureTech Parent Level
$387.2M
Cash Equivalents & Short-Term Investments at PureTech Parent Level as of September 30, 20208
8. PureTech Level Cash Reserves at September 30, 2020 represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $372.0 million and held at PureTech LYT Inc., our internal pipeline, of $15.2 million, all of which are wholly owned entities of PureTech, excluding cash balances and short-term investments of $38.3 million held at Controlled Founded Entities which are not wholly owned.
The BIG Idea - Moving medicine forward at PureTech
